within Pharmacolibrary.Drugs.ATC.P;

model P01AB02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1.0,
    Cl             = 5.833333333333333e-05,
    adminDuration  = 600,
    adminMass      = 2000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0009,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>P01AB02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Tinidazole is a synthetic antiprotozoal and antibacterial agent of the 5-nitroimidazole class. It is primarily used for the treatment of protozoal infections such as giardiasis, trichomoniasis, and amoebiasis, as well as for some anaerobic bacterial infections. Tinidazole is approved and widely used in clinical practice today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after a single oral dose.</p><h4>References</h4><ol><li><p>Mergenhagen, KA, et al., &amp; Russo, TA (2020). Fact versus Fiction: a Review of the Evidence behind Alcohol and Antibiotic Interactions. <i>Antimicrobial agents and chemotherapy</i> 64(3) –. DOI:<a href=&quot;https://doi.org/10.1128/AAC.02167-19&quot;>10.1128/AAC.02167-19</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31871085/&quot;>https://pubmed.ncbi.nlm.nih.gov/31871085</a></p></li><li><p>Lamp, KC, et al., &amp; Lacy, MK (1999). Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. <i>Clinical pharmacokinetics</i> 36(5) 353–373. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199936050-00004&quot;>10.2165/00003088-199936050-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10384859/&quot;>https://pubmed.ncbi.nlm.nih.gov/10384859</a></p></li><li><p>Wood, BA, &amp; Monro, AM (1975). Pharmacokinetics of tinidazole and metronidazole in women after single large oral doses. <i>The British journal of venereal diseases</i> 51(1) 51–53. DOI:<a href=&quot;https://doi.org/10.1136/sti.51.1.51&quot;>10.1136/sti.51.1.51</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1092424/&quot;>https://pubmed.ncbi.nlm.nih.gov/1092424</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end P01AB02;
